Study on Immunotherapy Combinations for Advanced Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• Be 18 years or older.
• Provide written informed consent to participate.
• Have a confirmed diagnosis of advanced non-small cell lung cancer (NSCLC) that cannot be removed by surgery or treated with chemoradiation, or has spread to other parts of the body.
• Have not received any prior treatment for advanced or metastatic NSCLC.
• Have high levels of PD-L1 protein in the tumor cells (Tumor Proportion Score of 50% or higher).
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have measurable cancer as defined by standard criteria.

Exclusion Criteria

• Have specific genetic mutations in the cancer for which targeted treatments are available, such as EGFR, ALK, or ROS1 mutations.
• Have received prior treatment with immune checkpoint inhibitors.
• Have active cancer that has spread to the brain.
• Have active and uncontrolled hepatitis B or C infections.
• Have uncontrolled HIV infection. Participants with controlled HIV (undetectable viral load and CD4 count above 350) are allowed.
• Have an active autoimmune disease or immune deficiency.
• Have a history of severe allergic reactions to the study drugs or similar medications.
• Have a history of lung diseases like interstitial lung disease or pneumonitis.
• Have a history of inflammatory bowel disease or colitis.
• Be on chronic steroid therapy at doses higher than 10mg/day of prednisone or equivalent.
• Have an active infection requiring antibiotics.
• Be pregnant or breastfeeding.
• Have had an organ transplant.
• Have any medical condition that the study doctor believes would prevent participation.